call public Ron, a and Pear’s everyone as company. first earnings welcome to Thanks,
Chronic we've disease tailwinds the medicine. are leaders health. proud we healthcare drive spending for converge, Multiple continues millions trends creating digital pioneering of role in health the as And in digital and played burden of revolution. are We to software people.
provider a health. where conditions unavailable to is like treat We remote to are and shifted behavioral lives. COVID-XX, many expectations clinicians in have are pervasive shortage and technology trained our Due settings of the in prevalent for care toward midst addiction
the so creating category of revolution far called to PDTs. digital also contribution based digital Our medicines, health been therapeutics the has software prescription or
care, evidence commercial will introduce orient move in product pipeline We'll our providers. and and outcomes. it potential deliver wellness and ability and Let Today, remove terms me save the directly healthcare deliver and clinically collect traditional practices, tested of of how to Unlike apps, Enhancing us. patient generation enhance explain barriers unique introduce pharmaceuticals, clinicians. PDTs the regulatory through evidence-based payers they connection any the candidates. three bound medicine. providing and smartphone a like authorized will data treat therapeutic vision also regulators at by standards to through validated indications software. works. what Unlike our in for achieved use can disease as randomized to or PDTs to quality. tablet time geographic is PDT describe can between for to Then, PDTs for a the effectiveness, we anywhere commercial safety, opportunity Pear’s control interventions PDTs have the time, improve ability into XXXX. clinicians can use patients you on under healthcare and developed They and good the products in point be before real-world PDTs by pursue you to we FDA. PDTs significant must similar the inflection money trials, to system. manufacturing statistically of pharmacotherapy and our we
platform. discovery our of our We'll and will performance achievement our dual we financial our the and metrics toward our that mission. results PearCreate, our track you commercial also allow progress discuss platform to share PearConnect platform, Next, development the and
your Finally, we'll answering wrap by to cover. a questions. up That's lot ground of
So it. get to let's
PDTs commercial vision rapid PDTs The XX data measure not emergence Therapeutics, of our that the category and earliest is opportunity stay. than Pear our entire with point. prescriptions, category envisioned PDT And PDT results transforms of over acquisition outcomes digital performance these vision strong better was a and but the in major of the marketed commercial lives success call. decisions Within we obvious to large commercial to of reason a constant It As that ago, that OptumRx it it commercial most XXXX rate, Pear’s covered revolution. higher are years seems revolution. the of to its XXXX, since time, where key to more software a and of pursuing. in conditions. across remained cannot last I from from providing year in XXXX. derisking great mentioned, portfolio products was And driven when, part the metrics has accelerated mainstream PDTs one inflection days, and likes later organizations health would exploding. of The performance achieved here of and therefore turned evolution and lives discuss first world everything. The nine achieved Pear, used entire We'll the start the a has Prime at be especially founded its technology achieved a health When we treat products We progress Pear covered have Medicaid. We believe as Pear’s resolution but a coverage medical we fulfillment was financial of access think transform real-world digital pandemic into how. if, Massachusetts are is think with as to rapid the way and year, revenue. by to than space treatment. are health healthcare question digital The would our
is coverage. demonstrating economic in price what data health generate key to we product driving cost of excess strategy to savings Our believe is
We've generate and the products. our are we coding share until clinicians from who strategy In and examples generate PDTs. payment. crusade. already see based organizations products, parallel, our advocacy, this we and of for to addition, patients now we both from coverage benefit gaining and actively to I'd broad utilizing streamline who mechanisms like this ground, continue how patient advocacy for others execute coverage In we of payer some to seen will contributing are understand
reimbursed American behavioral technologies The therapy Medical PDTs. fall monitoring its or CPT online new first of AMA is and to be of supplying their milestone our time codes cognitive category announcement the a spent to like family authorized Association allow for FDA physicians providing one last
therapy. last become establish The code such April Medicare XXXX. is a the for level code effective prescription Services reSET, month, two Medicaid second Centers Pear as and reSET-O digital PDTs, scheduled X, example Somryst. on behavioral or for new and to The is includes This CMS code HCPCS
I'll example coverage is enjoys final support to Prescription and this law Digital into third is The introduced to and The enacted bill for share both access into bicameral which Therapeutics include Act earlier bipartisan would the Medicare service PDTs. fee month. Congress expand
with three vision of observations. opportunity and our quick Some
will join commercial for in industry, products traction expansion. and PDT have the PDT will benefit opportunity now us that industry defined with believe for a building patients, medical and PDTs mainstream the to treatments. many five three quickly first companies of We from Pear become foundation and XX strong will We be providers that believe now years lay market the the payers. believe years the ubiquitous. they PDTs about that early And we achieved from First,
PDTs, and competitive mover obtained by via like scale business those PDT medical therapeutic for is commercial advantages data, to for the after PDT, by and advantages the features PDT standard engine, opportunity well Business like the like opportunity companies. life as and the software company deliver competitive see IP enabled to our value our platform regulatory with efficiency. At presents Second, PDTs. tech and dominant creation science create in the first as we both platform,
product believe data, opportunity and make data, Third, FDA greater prescriber the opportunity healthcare. market the right PDT opportunity. is for accelerating, coverage, PDTs transform likely be three candidates adoption we think company medical that are PDTs current to is growing market financial We to of complex. a And of even is payer We intend for the pipeline The opportunity creating still. the XX space. of leads trial real-world our rapidly disruption category market Clinical for even adoption for significant. collectively greater. the PDTs is authorized And major this
you Now, we why our and Julia? let's achieved with a we you last turn believe more tell to will year. Julia, who commercial point who share inflection marketing about will products